Skip to main content
SpringerLink
Log in

Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

In this work, we present a recently developed ruthenium complex that shows anticancer activity in gallbladder cancer cells.

Methods

After the synthesis of the new ruthenium complexes, the antiproliferative, cytotoxicity, and apoptosis activities were evaluated in vitro by the triple assay ApoTox-Glo. Then, the transcription levels of genes related to apoptosis were evaluated by real-time PCR (q-PCR).

Results

The ruthenium complex, called Ru-UCN3, inhibits the proliferation of gallbladder cancer cells G-415 by means of apoptosis, which was demonstrated by the overexpression of the pro-apoptotic genes Puma, Diablo, and Caspasa-9 together with the repression of the anti-apoptotic genes Bcl-xL and Bcl-2. In addition, we found strong caspase 3/7 activity in the cells at 24 h of the Ru-UCN3 exposure, which was evaluated by the triple ApoTox-Glo assay.

Conclusion

The new ruthenium complexes evaluated had an inhibitory effect on G-415 cells. We think that Ru-UCN3 could be a promising anticancer agent, which should be explored with more in vitro and in vivo assays and probably with the chemical modulation of this molecule.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Olivares LV. Cancer of the gallbladder—Chilean statistics. Ecancermedicalscience. 2016;10:704. https://doi.org/10.3332/ecancer.2016.704.

    Article  Google Scholar 

  2. DEIS. Departamento de Estadísticas e Información de Salud. 2018. http://www.deis.cl/defunciones-y-mortalidad-por-causas/. Accesed 27.11.18.

  3. Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol. 2017;23(22):3978–98. https://doi.org/10.3748/wjg.v23.i22.3978.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Zaidi MY, Maithel SK. Updates on gallbladder cancer management. Curr Oncol Rep. 2018;20(2):21. https://doi.org/10.1007/s11912-018-0664-3.

  5. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut and Liver. 2012;6(2):172–87. https://doi.org/10.5009/gnl.2012.6.2.172.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Utsumi M, Aoki H, Kunitomo T, Mushiake Y, Yasuhara I, Arata T, et al. Evaluation of surgical treatment for incidental gallbladder carcinoma diagnosed during or after laparoscopic cholecystectomy: single center results. BMC Res Notes. 2017;10:56. https://doi.org/10.1186/s13104-017-2387-1.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;16:279–81. PMID: 15668284.

    Article  CAS  Google Scholar 

  8. Thota S, Rodrigues DA, Crans DC, Barreiro EJ. Ru(II) compounds: next-generation anticancer metallotherapeutics? J Med Chem. 2018;61:5805–21. https://doi.org/10.1021/acs.jmedchem.7b01689.

    Article  CAS  PubMed  Google Scholar 

  9. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

    Article  CAS  Google Scholar 

  10. Kostova L. Ruthenium complex as anticancer agents. Curr Med Chem. 2006;13:1085–107. https://doi.org/10.2174/09298670677636094.

    Article  CAS  PubMed  Google Scholar 

  11. Klajner M, Licona C, Fetzer L, Hebraud P, Mellitzer G, Pfeffer M, et al. Subcellular localization and transport kinetics of ruthenium organometallic anticancer compounds in living cells: a dose-dependent role for amino acid and iron transporters. Inorg Chem. 2014;53(10):5150–8. https://doi.org/10.1021/ic500250e Epub 2014 May 1.

    Article  CAS  PubMed  Google Scholar 

  12. Kratz F, Keppler BK, Messori L, Smith C, Baker EN. Protein-binding properties of two antitumour Ru(III) complexes to human apotransferrin and apolactoferrin. Metal-Based Drugs. 1994;1(2–3):169–73. https://doi.org/10.1155/MBD.1994.169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Śpiewak K, Brindell M. Impact of low- and high-molecular-mass components of human serum on NAMI-A binding to transferrin. J Biol Inorg Chem. 2015;20(4):695–703. https://doi.org/10.1007/s00775-015-1255-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Allardyce CS, Dyson PJ. Ruthenium in medicine current clinical uses and future prospects. Platin Met Rev. 2001;45(2):62–69.

  15. Jaramillo P M, Hoyos SI. Carcinoma de vesícula biliar en el Hospital Pablo Tobón Uribe de Medellín. Revista Colombiana de Cirugía. (2009);24(4):250–257. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S2011-75822009000400007&lng=en.

  16. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. The oncologist. (2010);15(2):168–181. https://doi.org/10.1634/theoncologist.2009-0302.

  17. Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47:6645–53.

    Article  CAS  Google Scholar 

  18. Ndagi U, Mhlongo N, Soliman ME. Metal complexes in cancer therapy—an update from drug design perspective. Drug Des Devel Ther. 2017;11:599–616. https://doi.org/10.2147/DDDT.S119488.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ramírez-Rivera S, Pizarro S, Gallardo M, Gajardo F, Delgadillo A, De La Fuente-Ortega E, et al. Anticancer activity of two novel ruthenium compounds in gastric cancer cells. Life Sci. 2018;213:57–65.

    Article  Google Scholar 

  20. Lai S-H, Jiang G-B, Yao J-H, Li W, Han B-J, Cheng Z, et al. Cytotoxic activity, DNA damage, cellular uptake, apoptosis and western blot analysis of ruthenium(II) polypyridyl complex against human lung adecarcinoma A549 cell. J Inorg Biochem. 2015;152:1–9.

    Article  CAS  Google Scholar 

  21. Marta M, Elie BT, Pilar G, et al. Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(II) complexes. Dalton Trans. 2016;45:7049–66. https://doi.org/10.1039/C6DT00465B.

    Article  CAS  Google Scholar 

  22. Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:1–23. https://doi.org/10.1155/2014/150845.

    Article  CAS  Google Scholar 

  23. Matsuura K, Canfield K, Feng W, Kurokawa M. Metabolic regulation of apoptosis in cancer. Int Rev Cell Mol Biol. 2016;327:43–87. https://doi.org/10.1016/bs.ircmb.2016.06.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Villota H, Pizarro S, Gajardo F, Delgadillo Á, Cortés-Mancera F, Bernal G. Selective cytotoxicity of a novel compound based on ruthenium II in a gallbladder carcinoma cell line. In: Torres I, Bustamante J, Sierra D, editors. VII Latin American Congress on Biomedical Engineering CLAIB 2016, Bucaramanga, Santander, Colombia, October 26th -28th, 2016. IFMBE proceedings, vol. 60. Singapore: Springer; 2017. https://doi.org/10.1007/978-981-10-4086-3_74.

    Chapter  Google Scholar 

  25. Villota H, Pizarro S, Gajardo F, Delgadillo Á, Cortés-Mancera F, Bernal G. Apoptosis induced by a novel ruthenium II complex in a gallbladder carcinoma cell line. In: Torres I, Bustamante J, Sierra D, editors. VII Latin American congress on Biomedical Engineering CLAIB 2016, Bucaramanga, Santander, Colombia, October 26th -28th, 2016. IFMBE proceedings, vol. 60. Singapore: Springer; 2017. https://doi.org/10.1007/978-981-10-4086-3_75.

    Chapter  Google Scholar 

  26. Lima AP, Pereira FC, Almeida MAP, Mello FMS, Pires WC, Pinto TM, et al. Cytoxicity and apoptotic mechanism of ruthenium(II) amino acid complexes in sarcoma-180 tumor cells. PLoS One. 2014;9(10):e105865. https://doi.org/10.1371/journal.pone.0105865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Sharma G, Rana NK, Singh P, Dubey P, Pandey DS, & Koch B. p53 dependent apoptosis and cell cycle delay induced by heteroleptic complexes in human cervical cancer cells. Biomedicine & Pharmacotherapy. (2017);88:218–231. https://doi.org/10.1016/j.biopha.2017.01.044

  28. de Lima AP, de Castro Pereira F, Tiago CAS, et al. Induction of Cell Cycle Arrest and Apoptosis by RutheniumComplex cis-(Dichloro)tetramineruthenium(III) Chloridein Human Lung Carcinoma Cells A549. Biol Trace Elem Res. 2012. https://doi.org/10.1007/s12011-011-9275-7.

  29. Hoek J, Bloemendal KM, van der Velden LAA, van Diessen JNA, van Werkhoven E, Klop WMC, et al. Nefrotoxicidad como un factor limitante de la dosis en un régimen de quimiorradioterapia basada en cisplatino a dosis altas para los carcinomas de cabeza y cuello. Cánceres. 2016;8(2):21. https://doi.org/10.3390/cancers8020021.

    Article  CAS  Google Scholar 

  30. Stone JB, DeAngelis LM. Neurotoxicidad inducida por el tratamiento del cáncer: un enfoque en tratamientos más nuevos. Comentarios de la naturaleza. Clin Oncol. 2016;13(2):92–105. https://doi.org/10.1038/nrclinonc.2015.152.

    Article  CAS  Google Scholar 

Download references

Funding

This study was funded by CORFO - Chile 14IDL2-30087.

Author information

Authors and Affiliations

  1. Laboratorio de Biología Molecular y Celular del Cáncer, CáncerLab, Departamento de Ciencias Biomédicas, Facultad de Medicina, Universidad Católica Del Norte, Larrondo 1281, Coquimbo, 1781421, Chile

    Hernán Villota & Giuliano Bernal

  2. Facultad de Ciencias Exactas y Aplicadas- GI2B, Instituto Tecnológico Metropolitano, 73 # 76A – 354 vía al volador, Medellín, Colombia

    Hernán Villota & Fabián Cortés-Mancera

  3. Departamento de Química, Facultad de Ciencias, Universidad de La Serena, Benavente 980, La Serena, Chile

    Sebastian Pizarro, Francisco Gajardo & Álvaro Delgadillo

Authors
  1. Hernán Villota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sebastian Pizarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francisco Gajardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Álvaro Delgadillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabián Cortés-Mancera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giuliano Bernal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hernán Villota.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Villota, H., Pizarro, S., Gajardo, F. et al. Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells. J Gastrointest Canc 51, 571–578 (2020). https://doi.org/10.1007/s12029-019-00278-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-019-00278-x

Keywords

Search

Navigation